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Diabetic cardiomyopathy is initiated by alterations in energy substrates. Despite excess of plasma glucose and lipids, the diabetic
heart almost exclusively depends on fatty acid degradation. Glycolytic enzymes and transporters are impaired by fatty acid
metabolism, leading to accumulation of glucose derivatives. However, fatty acid oxidation yields lower ATP production per mole
of oxygen than glucose, causing mitochondrial uncoupling and decreased energy efficiency. In addition, the oxidation of fatty acids
can saturate and cause their deposition in the cytosol, where they deviate to induce toxic metabolites or gene expression by nuclear-
receptor interaction. Hyperglycemia, the fatty acid oxidation pathway, and the cytosolic storage of fatty acid and glucose/fatty acid
derivatives are major inducers of reactive oxygen species. However, the presence of these species can be essential for physiological
responses in the diabetic myocardium.
1. ROS Balance in the Diabetic Cardiac Cell
The number of mitochondria a cell contains depends on how
much energy the cell needs to produce. In particular, cardiac
cells comprise a large number ofmitochondria for continuous
aerobic respiration via oxidative phosphorylation [1]. These
organelles are responsible for 90% of the energy that cells
need to function; however,mitochondria are also the primary
source of reactive oxygen species (ROS) in mammalian cells














is a weak oxidizing agent. However, by a Fenton




yields ∙OH, the most oxidizing of
all cellular ROS. Moreover, ∙O
2
− can spontaneously combine
with NO radicals (∙NO) produced by inducible nitric oxide
synthase (iNOS) to form peroxynitrite (ONOO−), which
rapidly degrades to highly oxidant reactive nitrogen species
such as nitronium ion [3]. ROS are continuously produced
during many physiological processes in the cytosol and
mitochondria of cardiac cells mainly by four enzyme sys-
tems: the mitochondrial respiratory chain, NADPH oxidase
(NOX), xanthine oxidase, and endothelial NOS (eNOS)
[4]. However, ROS production can be in equilibrium with
the antioxidant capacity of the cell. In this sense, there
are some natural detoxification molecules that reduce or
scavenge ROS: enzymatic molecules, such as superoxide dis-
mutase (SOD), hemoxigenase-1 (HO-1), reduced glutathione
(GSH), glutathione peroxidase (GPox), and catalase, as well
as other nonenzymatic antioxidants, such as transferrin,
ferritin, and vitamins A, E, and C [5]. All of these antioxidant
systems can decrease the potency of particular reactive
species or render them completely harmless. Unfortunately,
this antioxidant defense may not counteract the prooxi-
dant effect developed in diabetic cardiomyopathy (DCM), a
unique entity bywhich diabetes affects heartmuscle indepen-
dently of any vascular disease or hypertension. In this sense,
Akhileshwar et al. demonstrated that while SOD and GPox
activities were increased in the diabetic rat heart, catalase and
GSH were ameliorated [6]. In this regard, by exogenous
antioxidant stimulation or ROS neutralization (i.e., by mod-
ulation of mitochondrial activity), scavenging (i.e., by inter-
ruption of ROS overproduction), or interference with ROS-
induced alterations (i.e., by regulation of ROS mediators),
various therapies have demonstrated an improvement in
DCM pathology [3, 5, 7].
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Figure 1: Paracrine and autocrine effects of ROS in DCM. ROS may be secreted from cardiomyocytes to induce responses in remote
(inflammatory) and neighboring (vascular, endothelial, and fibroblast) cells. Within the cardiomyocytes, ROS could also influence different
cytosolic (MAPK, PKC, and NOX) and mitochondrial mediators. mtDNA, mTF, and mPTP mean mitochondrial DNA, mitochondrial
transcription factors, and mitochondrial permeability transition pores, respectively.
2. ROS and Cell Signalling in DCM
ROS can be ideal signalling molecules due to the high com-
plexity and control by which they are synthesized and
degraded [8]. ROS contain one or more unpaired electrons,
making them extremely susceptible to interaction with bio-
logical molecules such as DNA, lipids, carbohydrates, and





with both the bases and the sugar residues of the nucleic acid
sequence. ROS-related oxidation of DNA is one of the main
causes of mutations, such as nonbulky (8-oxoguanine and
formamidopyrimidine) and bulky (cyclopurine and etheno
adducts) base modifications, abasic sites, nonconventional
single-strand breaks, protein-DNA adducts, and intra- or
interstrand DNA crosslinks [9]. Lipids, mostly polyunsatu-
rated fatty acids (FA), can be oxidized since they contain
multiple double bonds between which lie methylene bridges
that possess especially reactive hydrogens. The resultant FA
radical is unstable and reacts readily with molecular oxygen,
thereby creating a peroxyl-FA radical.This radical reacts with
another FA, yielding lipid peroxide, which can also cause
extremely oxidant products such as unsaturated aldehydes
(i.e., 4-hydroxy-2-nonenal (4-HNE)) and intensify lipid per-
oxidation [10]. Moreover, ROS interact with carbohydrates,
and the subsequent oxidized carbohydrates can glycate pro-
teins (by Maillard reactions) and form advanced glycation
products (AGEs). AGEs may be even more reactive than the
initial sugars they were constituted from. The mechanism by
which AGEs induce damage is through a process called
crosslinking (proteins can be covalently bonded forming
chains), which causes intracellular damage and apoptosis
[11]. Oxidations in proteins are described as posttranslational
modifications onmethionine/cysteine residues of several oxi-
doreductases, kinases, proteases, and transcription factors,
thus affecting downstream enzymatic activity, membrane
structure, and gene signalling [12]. In this manner, the heart
offers “redox-sensor” molecules that are highly susceptible to
the oxidative diabetic environment. Importantly, ROS may
interact on producer and neighboring cells during DCM.
2.1. Extracellular ROS Signalling. Once formed, ROS can be
released from cardiac cells and act in recruiting the first wave





, are membrane permeable and are, therefore,
potential candidates to signal other cells within the inflam-
matorymilieu, as occurs inDCM (Figure 1). Particularly, leu-





T-cells activate and proliferate following a ROS increase
[15]. Also, elevation of ROS in cardiac stem cells triggers a
paracrine secretion of growth factors such as insulin growth
factor-1 (IGF-1) and stromal-derived factor-1 (SDF-1) into
conditioned media [16]. Rapid depolarization of atrial myo-
cytes increases secretion of ROS, which stimulate the profi-
brotic expression in cocultured fibroblasts [17]. Moreover,
∙O
2
− may play a paracrine role in the regulation of vascular
function. It has been showed that ∙O
2
− induced cardiac NOX
activity and expression of the NOX subunit gp91phox in
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endothelial cells, leading to coronary endothelial dysfunction
[18]. ROS also play a crucial role in angiogenesis. Vascular
repair and expression of angiogenic genes including vascular
endothelial growth factor (VEGF), fibroblast growth factor
(FGF), and platelet-derived growth factor (PDGF) were
upregulated after cardiac secretion of ROS [19]. Thus, as a
stress-response mechanism, the diabetic myocardium could
release ROS to activate inflammation and other processes
(e.g., angiogenesis) in remote and neighboring areas.
2.2. Intracellular ROS Signalling. Cytosolic ROS are mainly
produced by NOX in the heart [20]. The redox state plays a
central role in multiple signalling cascades such as mitogen-
activated kinases (MAPKs) (Figure 1). ROS promote the
phosphorylation and activation of c-Jun NH2-terminal
kinases (JNKs), extracellular signal-regulated kinase-1/-2
(ERK1/2), p38-MAPKs, and the big MAPK-1 [21, 22]. In this
sense, the lack of p38 prevented ROS-induced apoptosis and
remodeling in DCM [23]. In addition, once activated,
MAPKs can transactivate several other kinases, growth fac-
tors, and transcription factors accompanied by the related
gene expression [24]. Nuclear factor 𝜅B (NF𝜅B), activating
protein-1 (AP-1), early growth response gene-1 (Egr-1), sur-
factant protein-1 (SP-1), and E26 transformation specific-1
(Ets-1) are ROS-induced transcription factors [25]. NF𝜅B is a
transcription factor that, as a part of a stress response, binds
promoters of a plethora of cytokines, chemokines, adhesion
molecules, and enzymes involved in secondary inflammatory
mediation. Interestingly, diabetic cardiac biopsies showed
higher NF𝜅B levels and subsequent NF𝜅B-target genes, like
TNF𝛼 [26]. Some data also provide evidence that protein
kinase-C- (PKC-) dependent redox Signalling affects cardiac
function [27]. The increase of PKC in diabetic hearts also
elevates the expression of angiotensin-II-converting enzyme
(ACE) and myosin heavy chain and interferes with proteins
involved in cardiac excitation-contraction coupling [28, 29].
Upon electrical stimulation, Ca2+ is released from the sar-
coplasmic reticulum to bind actin filaments, allowing cross-
bridges between actin and myosin. Ca2+ is a reuptake for a
new contractile cycle via Ca2+-ATPase-2a. Moreover, ROS
slow down sarcoplasmic Ca2+ uptake and decrease L-type
Ca2+ flow amplitude, damaging cell contraction [30]. Under
G-protein-dependent PLC activation and 1,2-diacylglycerol
(DAG) release, PKC is activated and stimulates transcription
factors such as nuclear factor of activated T-cells (NFAT)
and NF𝜅B [31]. Interestingly, low levels of cytosolic ROS
stimulate NF𝜅B, while high levels of cytosolic and nuclear
ROS inactivate NF𝜅B-DNA binding [12]. Finally, ROS have




Mitochondria are the major source of ROS in the cell.
Mitochondrial ROS are synthesized as a byproduct of oxygen
metabolism by the respiratory chain (from complexes I and
III, in the inner mitochondrial membrane) and by nonres-
piratory enzymes (i.e., monoamine oxidase, cytochrome B5,
or pyruvate dehydrogenase complex, in the outer membrane)
[33]. However, the bulk of mitochondrial ROS generation
occurs at the electron transport chain [2]. Moreover, ROS
can affect mitochondrial DNA (mtDNA), which is a closed-
circular double-strandedDNAmolecule of∼16.5 kb encoding
for components of the mitochondrial respiratory machinery
(13 polypeptides, 22 tRNAs, and 2 rRNAs) [34]. ROS can
also mediate the opening of mitochondrial permeability
transition pores (mPTP) by membrane lipid peroxidation,
stimulating increased inner membrane permeability, Ca2+
release, and ATP depletion in the diabetic myocardium [35,
36]. In addition, the activity of the mitochondrial transcrip-
tion factors A (Tfam), involved in mitochondria biogenesis,
can also be regulated by ROS [37, 38].
Therefore, both cytosolic and mitochondrial ROS could
regulate the activity and expression of multiple mediators in
the diabetic myocardium.
3. Diabetic Heart and ROS Generation
Most extracellular insults, such as concentration of energetic
substrates, can cause an increase of ROS, eventually surpass-
ing tissue demand [22]. Oxidative stress is defined as an over-
supply of ROS relative to the antioxidant defense. The
destructive role of ROS is attributed to their deforming prop-
erties on biological molecules and consequent influence on
cell fate and phenotype [13]. In diabetes, alteration of energy
substrates (i.e., excess of plasma glucose and lipids) can
directly or indirectly induce ROS formation in the myocar-
dium. DCM begins with a disturbance in the glucose meta-
bolism that provokes hyperglycemia. A feature common to all
cell types that are damaged by hyperglycemia is an increased
production of AGEs and ROS [39, 40]. High concentration
of glucose triggers AGEs synthesis, in particular, glycated
extra matrix proteins (e.g., collagens). AGEs bind specific
receptors (RAGE) to activate NOX and to release ROS [41]
(Figure 2(a)). PKC can also be stimulated by AGEs to phos-
phorylate proteins involved in Ca2+ handling and cardiomy-
ocyte contraction [42, 43]. In addition, acute exposure to
high glucose elevates iNOS gene expression and subsequent
∙NO, ∙O
2
−, and ONOO− [44], which in turn stimulate poly-
ADP ribose-polymerase-1 enzyme (PARP) as a compensatory
antioxidant mechanism. In this sense, hyperglycemia caused
upregulation of extracellular matrix proteins and cardiomy-
ocyte hypertrophy and increased oxidative stress in diabetic
hearts, and these alterationswere not found in the PARP(−/−)
mice and diabetic rats treated with a PARP inhibitor [45].
However, PARP inhibits the glycolytic enzyme glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), and thus it
induces glycolytic intermediate formation and, again, AGEs
[4, 45] (Figure 2(a)). High glucose concentration increases
the flux through the hexosamine biosynthetic pathway and
elevates N-acetylglucosamine, which has been associated
with insulin resistance and ROS production [46]. Further-
more, as a consequence of hyperglycemia, insulin resistance
and hyperinsulinemia elicit an elevation of plasma lipids in
diabetes. Obesity is also frequently present in the diabetic
patient, and lipolysis of adipose tissue is incompletely sup-
pressed, causing increased release of FA [47]. Several studies
have reported that hyperlipidemia induces overproduction of
mitochondrial ROS in diabetic patients [48].








































Figure 2: Hyperglycemia, hyperlipidemia, and myocardial ROS production. In diabetes, both the excess of plasma glucose (a) that cannot
be properly assimilated by the tissues and the abundance of plasma lipids (b) may induce oxidative stress in the heart by different mediators.
UCPs, uncoupling proteins.
The diabetic heart prefers FA as an energy substrate [49].
In type II diabetic patients, a twofold increase in cardiac
palmitate oxidation and a 30%–40% decrease in glucose
oxidation have been described [50]. Serum FA composi-
tion (cholesterol esters, phospholipids, and triacylglycerols
(TAG)) is roughly reproduced by the FA composition of the
diet [51]. However, plasma FA is also affected by other factors
such as gender and physical activity, and some FA can be
generated by de novo synthesis [52]. Most of the plasma lipids
are TAG, containing unbranched monocarboxylic FA with
at least sixteen carbons (long-chain FA). Depending on the
presence of double bonds, FA are classified as saturated (SFA,
without double bonds), monounsaturated (MUFA, with one
double bond), and polyunsaturated (PUFA, with at least two
double bonds). MUFA/PUFA and SFA can be converted
by desaturases/elongases in the endoplasmic reticulum (ER)
[53]. Among PUFA, linoleic and alpha-linolenic acids are
named “essential FA” (only obtained from the diet), and their
derivatives, such as arachidonic acid, play pivotal roles in
cardiac FA metabolism (see below). Importantly, exces-
sive levels of dietary fat or higher content of SFA versus
MUFA/PUFA has been implicated in the onset and pro-
gression of several chronic diseases, including diabetes
and obesity [54]. Cardiac cells can take up circulating FA
(as albumin associated with or coupled in lipoproteins)
by simple diffusion across the plasma membrane or by
FA transporters (i.e., FAT/CD36, FABPpm, and FATP1, -4,
and -6 [55] (Figure 2(b)). In particular, FAT/CD36 is respon-
sible for up to 60% of the FA uptake in the heart and, like the
glucose transporter (Glut4), can traffic between endosomes
and plasmamembrane following stimulation (insulin,muscle
contraction, and AMPK activation) [56]. Once in the cells,
membrane-associated acyl-CoA synthetases generate acyl-
CoAs (fromFAand coenzyme-A) thatmay provide substrates
for membrane structure, energy metabolism, and signalling
molecules. Nonetheless, an overload of acyl-CoAs can satu-
rate FA delivery and deviate to undesirable outcomes. In the
diabeticmyocardia, both lipid degradation and accumulation
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cause cytosolic and mainly mitochondrial ROS release [57].
However, lipid may also decrease the oxidation state by
regulating specific gene expression.
3.1. 𝛽-Oxidation and ROS Production. Acyl-CoAs are rapidly
metabolized by peroxisomal and, mainly, mitochondrial 𝛽-
oxidation, leaving intracellular acyl-CoA concentration at
very low levels (<10 𝜇M) [58]. The transport of acyl-CoA
into the mitochondria is accomplished by an acylcarnitine
intermediate, which is generated by the carnitine palmi-
toyltransferase (CPT) system at the mitochondrial outer
and inner membranes. Once inside the mitochondrion,
acyl-CoA is the substrate for the 𝛽-oxidation machin-
ery in which a carbon at the 𝛽-position is oxidized in
every round of the cycle (Figure 2(b)). Several flavin adenine
dinucleotide- (FAD-) dependent acyl-CoA dehydrogenases
and a mitochondrial trifunctional enzyme (with enoyl-CoA
hydratase, 3-hydroxyacyl-CoA dehydrogenase, and thiolase
activities) compose this pathway. Each round of 𝛽-oxidation
produces one mole of each FADH
2
, NADH, and acetyl-
CoA. The latter enters into the tricarboxylic-acid cycle to
oxidize CO
2
and generate three moles of NADH and one
mole of each FADH
2
and ATP. Then, all generated NADH
and FADH
2
are used within the respiratory pathway for
the production of more ATP via oxidative phosphoryla-
tion. In this process, ROS, mostly, ∙O
2
−, are constitutively
produced when both NADH and FADH
2
directly react
with oxygen [59]. In the diabetic myocardium, increased
acyl-CoA and 𝛽-oxidation trigger the delivery of reducing
equivalents (NADH and FADH
2
) to the electron transport
chain and the generation of ROS [60, 61] (Figure 2(b)). Also,
the increase in FA metabolism in the diabetic heart has been
associated with an increased expression of mitochondrial
uncoupling proteins (UCP). In particular, FA can induce
UCP3 via PPAR𝛼 activation [62]. However, despite the fact
that mitochondrial uncoupling serves to limit the production
of ROS (by reducing proton gradient), uncoupling can be
deleterious since it lowers the production of ATP, thereby
making the heart less efficient. In addition, the excess of acyl-
CoAalso activates the peroxisomal𝛽-oxidation inDCM.This
process plays an important role in overall FA metabolism
of the diabetic heart, mainly for very long-chain acyl-CoA
and acyl-CoA derivatives. However, first oxidation steps in
peroxisomes are not coupled to energy production, implying
an extra source of ROS [60].
3.2. Lipid Derivatives and ROS Generation. In the diabetic
heart, an overloaded 𝛽-oxidation can saturate the mitochon-
dria, leading to the accumulation of acyl-CoA in the cytosol.
The deposition of acyl-CoA in nonadipose tissues is called
steatosis. Myocardial steatosis may lead to cell dysfunction
and death. In addition to recycling to TAG by esterification
(Figure 2(b)), acyl-CoAs can be rapidly assimilated into com-
plexes such as phospholipids and mainly sphingolipids (e.g.,
ceramides and glycosylceramides) at the ER [48]. Especially,
SFA, but not PUFA or MUFA, are converted to sphingolipids
by the serine-palmitoyl-CoA transferase activity. Sphin-
golipids possess both signalling and structural properties, and
some of them, like sphingosine-1 phosphate, are antioxidant
and cardioprotective [63]. However, others like ceramides
may cause cardiac failure. In this sense, in various rodent
models of diabetes, increased myocardial ROS and ceram-
ide content have been associated with cardiac dysfunction
[64]. Ceramides also promoted apoptosis, insulin resistance,
autophagy, and inflammation [63] and acted also directly
on mitochondria to inhibit complex III and generate ROS
and inflammation [65] (Figure 2(b)). Ceramides activate pro-
apoptotic protein phosphatase-1 or -2A (PP1 or PP2A) and
cathepsinD [66]. In addition, ceramides have been showed to
inhibit Ca2+ release and cell contraction in the diabetic myo-
cardium [67]. Methods to reduce cardiac ceramide synthesis,
including the decrease of FA uptake and conversion of FA to
nontoxic TAG, have demonstrated beneficial effects [66].
3.3. Lipid Signalling and ROS Control. Lipids have also been
recognized as function-like nuclear signalling molecules.
Acyl-CoAs can be transported to the nucleus by FA-binding
proteins [68]. SFA, MUFA, or PUFA and, in this case, arachi-
donic acid metabolites such as eicosanoids (prostaglandins,
leukotrienes, thromboxanes, and lipoxins) can regulate lipid
homeostasis and oxidation by interacting with nuclear recep-
tors. Of the five nuclear-receptor families reported to bind
acyl-CoAs, only peroxisome proliferator-activated receptors
(PPARs) are well accepted as FA-regulated nuclear receptors
[69]. Two isotypes of PPARs are mostly expressed in the
myocardium (PPAR𝛼 and PPAR𝛽/𝛿). Based on their struc-
tural and chain composition, acyl-CoAs will show different
affinity for the PPAR subtypes [53]. PPARs heterodimerize
with retinoid-X receptors (RXR) and mediate transcrip-
tional activation by binding to specific DNA promoter
sequences in target genes. Activation of PPAR𝛼 and PPAR𝛽/𝛿
is linked to the upregulation of several genes involved in
FA uptake, binding, and 𝛽-oxidation, and, thus, PPARs
promote ROS generation in both peroxisomes and mito-
chondria [70, 71] (Figure 2(b)). However, pharmaceutical
stimulation of PPAR𝛼 and PPAR𝛽/𝛿 induces an increase
of 𝛽-oxidation and reduction of lipid accumulation and
cardiac dysfunction. Intriguingly, in contrast with PPAR𝛽/𝛿-
transgenic mice, PPAR𝛼-overexpressing mice develop car-
diac hypertrophy and dysfunction, associated with myocar-
dial lipid accumulation and high FA uptake and utilization
rates [72, 73]. This pathology has been linked to the excess of
ROS production. PPAR𝛼 activation can also decrease glucose
utilization by increasing the expression of pyruvate dehydro-
genase kinase-4 (PDK4), and the agonism of PPAR𝛼 elevates
cardiac ceramide levels and leads to cardiac dysfunction [74].
In addition, exogenous simulation of PPAR𝛽/𝛿 could also
prevent the expression of NOX subunits (p22(phox) and
p47(phox)) and, resulting elevation of NOX activity and ∙O
2
−
production [75]. In this sense, some PPAR-acyl-CoA com-
plexes can also regulate gene expression of prooxidant signals,
such as NF𝜅B, in a DNA-independent way (Figure 2(b)).
PPARs sequestrate NF𝜅B coactivators and/or stimulate I𝜅B𝛼
(the NF𝜅B inhibitory subunit) to prevent NF𝜅B translocation
to the nucleus and later oxidation/inflammation [76, 77].
Altogether, the use of exogenous ligands for specific PPAR
isoforms may overexpress FA-metabolic genes but may also
compensate the oxidative stress by regulation of prooxidant
genes and NF𝜅B.
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Figure 3: Pathological responses mediated by ROS in the diabetic
heart. ROS are involved in the proinflammatory, -hypertrophic, and
-fibrotic as well as cell-death processes developed in the diabetic
myocardium.
4. Deleterious Effects of ROS in DCM
In the initial step of DCM, patients exhibit diastolic heart
failure with normal ejection fraction often associated with
hypertrophy. Later, patients present systolic and diastolic
heart failure with dilatation and reduced ejection fraction
(stage 2). Patients with additional myocardial inflammation
(and/or microvascular disease) are classified as DCM stage 3.
Finally, patients with ischemia, infarction, and remodelling
are enclosed in DCM stage 4 [78]. Importantly, the under-
lying cellular processes including inflammation and hyper-
trophy, myocyte apoptosis and necrosis, and deposition of
extracellular matrix have a direct correlation with the oxida-
tive state of the cardiac cell (Figure 3).
4.1. ROS and Cardiac Inflammation. Obesity and type II dia-
betes are characterized by a state of low-grade inflammation
[79]. The hypoxic and prooxidant status of the diabetic heart
is usually characterized by elevated production and release of
proinflammatory cytokines (such as TNF𝛼 and IL-6), which
activate the NF𝜅B signalling, macrophage and T-cell recruit-
ment, and leukocyte cardiac infiltration [80, 81]. Epicardial
adipose tissue, which is increased in obese patients, may
interact with myocardium through secretion of proinflam-
matory cytokines [82]. ROS also trigger PARP, which in turn
activates NF𝜅B and proinflammatory genes [4]. Some data
also provide evidence that p38- and PKC-dependent redox
signalling are involved in cardiac inflammation [83, 84].
Importantly, recruited inflammatory cells can also release
TNF𝛼 and IL-6, enhancing inflammation. In this regard, ROS
mediate upregulation of MCP-1, and this chemokine also
stimulates ROS production [85, 86]. MMP9, a metalloprote-
inase regulated by ROS, also increases inflammation by stim-
ulation of proinflammatory TNF𝛼 [87]. Of interest, specific
acyl-CoAs like SFA may directly bind and activate proin-
flammatory Toll-like receptor-4 (TLR4) [88]. In this regard,
TLR4-deficient diabetic mouse hearts showed lower TAG
accumulation and improved cardiac function [89]. On
the other hand, hyperglycemia can induce epigenetic modifi-
cations on histones that increase the expression of p65 NF𝜅B
subunit and consequent inflammation [90]. In this regard,
exposure to high glucose also caused overexpression of IL-
6 andMCP-1 through decreased histone-3 methylation at the
cytokine promoter [91].
4.2. ROS and Cardiac Hypertrophy. The development of
cardiac hypertrophy may involve an increase in mitochon-
drial ROS and mitochondrial DNA damage [92]. However,
hypertrophy may also be a consequence of distinct stimu-
lated sources of ROS, including mechanical strain, and the
activation of G-protein-coupled receptors, receptor tyrosine
kinases, and natriuretic peptides [93]. Ligands for G-protein-
coupled receptors (e.g., angiotensin-II, endothelin-1, and
adrenaline) induce hypertrophy by NOX-ROS-dependent
mediators such as Erk1/2 and NF𝜅B [94]. Other signalling
pathways involved in hypertrophy are potentially subject to
redox regulation, such as PI3K/Akt, PKA, JAK-STAT, and
NFAT [95]. ROS also activate MAPK andMMPs, which con-
tribute to cardiac growth and hypertrophic responses [24,
96]. Angiotensin-II, a key effector of the renin-angiotensin-
aldosterone system (RAAS) involved in the progression of
myocardial hypertrophy to heart failure in diabetes, is also
activated by ROS [97]. Finally, induction of hypertrophic
markers such as brain natriuretic peptide (BNP) may depend
on ROS-activated NF𝜅B [98].
4.3. ROS and Cardiac Fibrosis. In DCM, the development of
fibrosis involves not only fibroblasts but also cardiomyocytes
and endothelial and inflammatory cells. Interstitial fibrosis is
a key component in cardiac dysfunction typically linked to
RAAS activation in a proinflammatory atmosphere, with
transforming growth factor-𝛽 (TGF𝛽) signalling and changes
in redox balance as pivotal effectors [94]. Both angiotensin-II
and TGF𝛽 stimulate transformation of interstitial fibroblast
into myofibroblasts by a NOX-dependent redox regulation
[99, 100]. Angiotensin-II also increases activating protein-
1 (AP-1) and related profibrotic genes, such as endothelin-1
[101]. ROS trigger latent TGF𝛽 and other profibrotic factors,
such as connective tissue growth factor (CTGF) [102]. In
addition, direct evidence implicating NOX in cardiac fibrosis
comes from studies in genetically modified mice. NOX2-null
mice showed significantly reduced interstitial fibrosis after
RAAS activation [103]. Nevertheless, NOX and ROS can
induce metalloproteinase (i.e., MMP9) expression, which
degrades extracellular matrix and attenuates fibrosis [104,
105]. In this sense, activated PPAR𝛼 or PPAR𝛽/𝛿 by lipids
can also interact with Smads and reduce the TGF𝛽 response
(Figure 2(b)), suggesting PPAR-associated antifibrotic prop-
erties [106, 107].
4.4. ROS and Cardiac Cell Death. Although cell death
scarcely occurs in the healthy myocardium (myocytes rarely
proliferate in adult cardiac muscle), it is a feature of endstage
heart failure. In the diabetic heart, the cell death-induced
event is mainly represented by apoptosis and necrosis [49].
The former entails two major signalling pathways, extrinsic
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and intrinsic, with limited crosstalk between the two. Basi-
cally, in the extrinsic via, death ligands such as TNF𝛼 or Fas
ligand bind to cognate receptors on the plasma membrane.
These receptors contain an intracellular death domain, which
recruits and activates caspase-8 through specific adaptors
(i.e., TRADD or FADD (TNFR1-associated or Fas-associated
death domain proteins, resp.)).Then, caspase-8 activates cas-
pase-3, resulting in apoptosis. Interestingly, ROS overexpress
TNF𝛼 by an apoptosis signal-regulating kinase-1- (ASK1-)
NF𝜅B-dependent pathway [36]. Moreover, NF𝜅B can be
involved in the upregulation of proapoptotic genes including
FasL, Fas, c-Myc, and p53 [108–110], and ROSmediate down-
regulation of antiapoptotic factors like FLIP (FLICE/caspase-
8 inhibitory protein) [111]. On the other hand, in type I dia-
betic hearts, ROS stimulate the epigenetic repression of cell
cycle inducers, such as cyclin D1 [112].
In the intrinsic pathway, the oxidizing mitochondria are
critical for the fate of the diabetic heart. Awide range ofmito-
chondrial ROS-induced damages have been described in the
mitochondrion, in particular, on its mPTP [2]. Oxidative
modifications of proteins of the mPTP deregulate the mito-
chondrial anion fluxes allowing the entry of small solutes into
the matrix [113]. Mitochondrial membrane potential is dissi-
pated, ATP production declines, and matrix swells due to the
movement ofwater from interstitial spaces (osmotic swelling)
[114]. Cytochrome-C, which is tightly attached to the inner
mitochondrial membrane by association with cardiolipin,
is liberated to the cytosol to form the Apaf-1-procaspase-
9 apoptosome complex that activates downstream effector
caspases [115]. Nonscavenged ROS can also stimulate pro-
apoptotic Bcl-2 family members, such as Bax and Bak [35].
Also, diverse components of the antioxidant defense and the
complexes I-IV of the respiratory chain are closely exposed
to ROS. The oxidation of these proteins decreases their
enzymatic activity and disturbs the whole respiratory process
[7, 116]. Mitochondria have a limited repair activity against
DNA damage since they do not have complex chromatin
organization, introns, or potent DNA-protecting enzymes
[38]. Thus, ROS and lipid peroxides can also attack mtDNA.
In the diabeticmitochondria, ROSmodify the transcriptional
activity of Tfam and thus decrease the expression of target
genes such as cytochrome-B and ATP synthase subunit-6
[37, 38]. Furthermore, lipid peroxides and ∙OH− may affect
membrane fluidity/permeability by oxidizing MUFA/PUFA
phospholipids [117]. In addition, diabetic mitochondria can
be autophagied (a process named mitophagy) in a redox-
dependent way. Mitophagy initially responds to a surviving
mechanism, but, later, it consists of a lethal response alterna-
tive to apoptosis [118].
Finally, as with other cardiomyopathies, in DCM, necro-
sis occurs as an uncontrolled process involving a robust
inflammatory component.Moderated quantities of ROS elicit
cell apoptosis, but high amounts initiate cell necrosis. Dia-
betes leads to cardiac apoptosis before necrosis, and, when
necrosis occurs, ventricular dysfunction follows [119]. Necro-
sis is a cell death lacking the characteristics of programmed
cell death and characterized by early plasma membrane
rupture and swelling of cytoplasmic organelles, in particular,
mitochondria [120]. This rupture also results in the leakage
of intracellular contents into the extracellular compartment
with stimulation of inflammatory process and collagen accu-
mulation. The intracellular Ca2+ overloading observed in
diabetes induces intramitochondrial Ca2+ excess, which
increases oxidative stress andmPTP opening and consequent
osmotic swelling, organellar dysfunction, and necrosis [121].
Activation of the RAAS correlates with increased oxidative
stress and necrosis in cardiomyocytes of diabetic patients
[122]. Intriguingly, the coexistence of diabetes and hyper-
tension increases necrosis, whereas there is no additional
increase in apoptosis. Also, the resistance to IGF-1 observed
in diabetes results in myocyte necrosis and myocardial
dysfunction [123].
5. Conclusions
In the diabetic heart, several factors can trigger ROS pro-
duction, especially, the excessive FA accumulation and meta-
bolism. Unfortunately, natural ROS defenses cannot neutra-
lize these deleterious substances and therefore leave the myo-
cardium exposed to oxidative attacks on protein, lipids, and
DNA of critical intracellular pathways and organelles,
enhancing inflammatory, hypertrophic, fibrotic, and cell-
death events in the diabetic myocardium. Antioxidant treat-
ments have demonstrated beneficial effects in DCM pathol-
ogy. However, ROS can also play key functions in the physiol-
ogy of the cardiac diabetic scenario. Alternatively, exogenous
stimulation of PPAR isoforms, such as PPAR𝛽/𝛿, may facil-
itate lipid degradation and control of prooxidant mediators
such as NOX and NF𝜅B.
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